UBS Reiterates Buy Rating on Cardinal Health (CAH)

UBS analyst Kevin Caliendo reiterated a Buy rating and $185.00 price target on Cardinal Health (NYSE: CAH).

The analyst commented, "On higher estimates, we are raising our PT to $185 (from $170). Our PT is now based on a 17x NTM + 12Me multiple (up from 16x) as we believe shares should trade closer to peers (CAH shares trade at 17x consensus' NTM EPS, in-line with COR and below MCK's 19x)."

For an analyst ratings summary and ratings history on Cardinal Health click here. For more ratings news on Cardinal Health click here.

Shares of Cardinal Health closed at $161.41 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• Greenway Technologies board member Raymond Wright resigns
• SpaceX files for 555.56M share IPO at $135/sh